Table 3 Prognostic impact of CDX2 expression and CRC subtypes, tumour budding and WHO grade in microsatellite subgroups of the overall cohort.
Overall cohort | Overall, n (%) | Mean overall survival (SE) | P value | Mean disease-specific survival (SE) | P value | Mean disease-free survival (SE) | P value | |
|---|---|---|---|---|---|---|---|---|
Microsatellite status: MSS subcohort | 0.012 | <0.001 | <0.001 | |||||
CDX2 expression | CDX2-low/absent | 63 (7.4%) | 87.19 (11.32) | 94.71 (11.69) | 87.56 (11.85) | |||
CDX2-high | 786 (92.6%) | 127.48 (4.42) | 154.65 (4.16) | 148.30 (4.21) | ||||
Microsatellite status: MSI-high subcohort | 0.083 | 0.223 | 0.198 | |||||
CDX2 expression | CDX2-low/absent | 39 (25.3%) | 114.33 (16.65) | 157.33 (15.27) | 148.10 (16.49) | |||
CDX2-high | 115 (74.7%) | 138.31 (8.11) | 160 (7.32) | 157.83 (7.40) | ||||
Microsatellite status: MSS subcohort | <0.001 | <0.001 | <0.001 | |||||
Tumour budding activity | Bd1 | 435 (51.2%) | 159.06 (5.04) | 190.86 (3.96) | 190.31 (3.78) | |||
Bd2 | 231 (27.2%) | 108.09 (7.60) | 128.72 (7.68) | 108.26 (7.64) | ||||
Bd3 | 183 (21.6%) | 49.29 (4.84) | 57.00 (5.64) | 49.40 (5.59) | ||||
Microsatellite status: MSI-high subcohort | <0.001 | <0.001 | <0.001 | |||||
Tumour budding activity | Bd1 | 110 (71.4%) | 151.11 (7.80) | 177.36 (5.81) | 171.86 (6.43) | |||
Bd2 | 30 (19.5%) | 108.11 (17.08) | 137.11 (18.46) | 147.09 (17.60) | ||||
Bd3 | 14 (9.1%) | 36.22 (11.87) | 32.71 (10.37) | 24.76 (9.53) | ||||
Microsatellite status: MSS subcohort | <0.001 | <0.001 | <0.001 | |||||
WHO grade | Low grade | 602 (70.9%) | 132.70 (4.67) | 160.66 (4.30) | 152.86 (4.33) | |||
High grade | 247 (29.1%) | 96.98 (6.69) | 112.11 (7.20) | 106.25 (7.39) | ||||
Microsatellite status: MSI-high subcohort | 0.128 | 0.166 | 0.201 | |||||
WHO grade | Low grade | 83 (53.9%) | 149.00 (11.18) | 171.27 (10.30) | 170.35 (9.75) | |||
High grade | 71 (46.1%) | 120.51 (10.42) | 149.05 (9.88) | 145.30 (10.23) | ||||
Microsatellite status: MSS subcohort | <0.001 | <0.001 | <0.001 | |||||
CRC subtypes | Adenocarcinoma NOS | 562 (66.2%) | 134.61 (5.24) | 162.19 (4.74) | 156.13 (4.79) | |||
Mucinous adenocarcinoma | 55 (6.5%) | 94.01 (10.93) | 111.43 (11.65) | 101.17 (11.96) | ||||
Signet-ring cell carcinoma | 6 (0.7%) | 15.13 (7.49) | 15.13 (7.49) | 12.34 (6.23) | ||||
Medullary adenocarcinoma | 4 (0.5%) | 129.68 (24.43) | 129.68 (24.43) | 128.47 (22.01) | ||||
Micropapillary adenocarcinoma | 117 (13.8%) | 79.68 (9.19) | 89.14 (9.92) | 77.00 (9.75) | ||||
Serrated adenocarcinoma | 73 (8.6%) | 113.79 (11.33) | 137.73 (11.13) | 133.81 (11.49) | ||||
Adenoma-like adenocarcinoma | 28 (3.2%) | 138.34 (13.24) | 175.78 (6.57) | 167.94 (9.68) | ||||
MANEC/NEC | 4 (0.5%) | 9.23 (4.90) | 9.23 (4.90) | 8.07 (3.25) | ||||
Microsatellite status: MSI-high subcohort | 0.338 | 0.007 | 0.019 | |||||
CRC subtypes | Adenocarcinoma NOS | 68 (44.2%) | 145.93 (11.85) | 169.73 (10.73) | 172.25 (10.00) | |||
Mucinous adenocarcinoma | 28 (18.2%) | 111.37 (15.54) | 128.41 (15.68) | 123.49 (15.84) | ||||
Signet-ring cell carcinoma | 3 (1.9%) | 82.13 (46.93) | 82.13 (46.93) | 80.25 (48.26) | ||||
Medullary adenocarcinoma | 28 (18.2%) | 142.62 (14.86) | 187.09 (7.40) | 179.72 (10.08) | ||||
Micropapillary adenocarcinoma | 5 (3.2%) | 38.56 (14.61) | 38.56 (14.61) | 35.22 (16.06) | ||||
Serrated adenocarcinoma | 14 (9.1%) | 132.57 (18.59) | 140.75 (17.87) | 120.05 (20.30) | ||||
Adenoma-like adenocarcinoma | 5 (3.2%) | 98.87 (26.65) | 139.70 (28.49) | 143.46 (29.84) | ||||
MANEC/NEC | 3 (1.9%) | 38.46 (14.52) | 38.46 (14.52) | 38.46 (14.51) |
